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Acinetobacter baumannii is a nosocomial opportunistic pathogen that can cause severe infections, including hospital-acquired
pneumonia, wound infections, and sepsis. Multidrug-resistant (MDR) strains are prevalent, further complicating patient treat-
ment. Due to the increase in MDR strains, the cationic antimicrobial peptide colistin has been used to treat A. baumannii infec-
tions. Colistin-resistant strains of A. baumannii with alterations to the lipid A component of lipopolysaccharide (LPS) have been
reported; specifically, the lipid A structure was shown to be hepta-acylated with a phosphoethanolamine (pEtN) modification
present on one of the terminal phosphate residues. Using a tandem mass spectrometry platform, we provide definitive evidence
that the lipid A isolated from colistin-resistant A. baumannii MAC204 LPS contains a novel structure corresponding to a
diphosphoryl hepta-acylated lipid A structure with both pEtN and galactosamine (GalN) modifications. To correlate our struc-
tural studies with clinically relevant samples, we characterized colistin-susceptible and -resistant isolates obtained from patients.
These results demonstrated that the clinical colistin-resistant isolate had the same pEtN and GalN modifications as those seen in
the laboratory-adapted A. baumannii strain MAC204. In summary, this work has shown complete structure characterization
including the accurate assignment of acylation, phosphorylation, and glycosylation of lipid A from A. baumannii, which are im-
portant for resistance to colistin.
The opportunistic pathogen Acinetobacter baumannii is aGram-negative aerobic coccobacillus and is a leading cause of
nosocomial infections globally (1–4). Infections include hospital
and community-acquired pneumonia, wound infections, and
sepsis, leading to increased mortality. Additionally, A. baumannii
has emerged as a major pathogen in U.S. military personnel in
field hospitals in Iraq and Afghanistan (5, 6). A. baumannii strains
have developed antimicrobial resistance, including resistance to
the cationic microbial peptide (CAMP) colistin (polymyxin E),
complicating patient treatment and furthering the cause for the
development of new antimicrobial therapies. Thus, A. baumannii
has emerged as a pathogen of great clinical concern.
Initial research on A. baumannii pathogenesis focused on de-
fining the genes and mechanisms responsible for antimicrobial
resistance. The capsular polysaccharide and lipopolysaccharide
(LPS), the major component of the Gram-negative bacterial cell
wall, act in concert to block access of complement to the cell wall,
inhibiting bacterial membrane lysis. LPS is located in the outer
leaflet of the outer membrane of Gram-negative bacteria and con-
sists of lipid A, the core oligosaccharide, and the O-specific anti-
gen. Lipid A is the bioactive component of LPS and is responsible
for activating the innate immune system via toll-like receptor 4
(TLR4), which potentially initiates a cascade of inflammatory cy-
tokine production that, if unchecked, can lead to septic shock.
Modifications of lipid A can drastically alter its immunostimula-
tory ability as well as resistance to antibiotics. For example, the
addition of positively charged residues including ethanolamine,
aminoarabinose, and glucosamine to lipid A modulates CAMP
resistance (Fig. 1) (7–9).
A previous report shows that a colistin-resistant (Colr) strain of
A. baumannii contained a pEtN addition with suggested acyl chain
positioning for the hepta-acylated lipid A structure (10, 11). Using
a tandem mass spectrometry platform and the laboratory-adapted
MAC204 colistin-resistant strain, we confirmed the addition of
pEtN and identified a novel second amino sugar modification,
GalN. To correlate our structural observations with clinically rel-
evant samples, we analyzed lipid A extracted from matched colis-
tin-susceptible (Cols) and -resistant A. baumannii isolates from
individual patients before and after colistin treatment. Using a
multifaceted mass spectrometric platform, we observed similar
lipid A structures with phosphoethanolamine (pEtN) and galac-
tosamine (GalN) additions that were present only in resistant
strains from patients treated with colistin. Taken together, the
pattern and location of lipid A acylation, phosphorylation, and
glycosylation potentially underpin a critical role in the overall
ability of A. baumannii to present resistance to colistin.
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MATERIALS AND METHODS
Bacteria. Acinetobacter baumannii colistin-resistant strain MAC204 was
provided by Mark Adams, Case Western University, Cleveland, OH.
Strain ATCC 17978 was obtained from the ATCC (American Type Cul-
ture Collection, Manassas, VA, USA). Strain MAC204 was generated by
inducing spontaneous mutants of the wild-type A. baumannii strain
MAC203 (12), a strain that was isolated from late-exponential-phase cul-
tures by selection on Lysogeny Broth (LB; Difco) plates containing 1.5%
agar and 1 g/ml colistin, resulting in strain ATCC 17978 Colr (MAC201).
This strain was used to select for colistin-susceptible revertants by growth
without colistin resulting in strain ATCC 17978 Colr_Rev (MAC203).
This strain was subsequently selected for colistin resistance as described
above, except 2 g/ml colistin was used in selection, resulting in strain
MAC204.
Three pairs of colistin-susceptible and -resistant isolates, 1494/1508
(JA637), 2382/2384 (JA566), and 2949/2949A (JA942), respectively, col-
lected from three individual patients, were provided by Yohei Doi, Uni-
versity of Pittsburgh Medical Center (see Table S1 in the supplemental
material) under IRB number PRO12060302. Clinical isolates were grown
overnight at 37°C in LB supplemented with 1 mM MgCl2. Susceptibility
profiles were determined by Etest (bioMérieux, St. Louis, MO), according
to the manufacturer’s procedures. The bacteria were grown in LB supple-
mented with 1 mM MgCl2 and 2 g/ml colistin at 37°C in a shaking
incubator at 250 rpm for 20 h (8).
LPS and lipid isolation and purification. LPS was extracted using a
hot phenol-water method (13). Freeze-dried bacteria were resuspended in
endotoxin-free water at a concentration of 10 mg/ml. A 12.5-ml volume of
90% phenol was added, and the resultant mixture was vortexed and incu-
bated in a hybridization oven at 65°C. The mixture was cooled on ice and
centrifuged at 10,000 rpm at room temperature for 30 min. The aqueous
phase was collected, and an equal volume of endotoxin-free water was
added to the organic phase. The sample was treated as above, and the
aqueous phases were combined, dialyzed against Milli-Q purified water to
remove residual phenol, frozen, and then freeze-dried. The resultant pel-
let was resuspended at a concentration of 10 mg/ml in endotoxin-free
water, treated with DNase (Sigma, St. Louis, MO) at 100 g/ml and RNase
A (Sigma) at 25 g/ml, and incubated at 37°C for 1 h in a water bath.
Proteinase K (Sigma) was added to a final concentration of 100 g/ml and
incubated for 1 h in a 37°C water bath (14). The solution was then ex-
tracted with an equal volume of water-saturated phenol. The aqueous
phase was collected and dialyzed against Milli-Q purified water and
freeze-dried as above. The LPS was further purified by the addition of
chloroform-methanol (2:1, vol/vol) to remove membrane phospholipids
(15) and further purified by an additional water-saturated phenol extrac-
tion and 75% ethanol precipitation to remove contaminating lipoproteins
(16). For mass spectrometry (MS) structural analysis, 1 mg of purified LPS
was converted to lipid A by mild-acid hydrolysis with 1% sodium dodecyl
sulfate (SDS) at pH 4.5 as described previously (17). Resulting lipid A was
analyzed using mass spectrometry as described below.
Small-scale lipid A isolation from whole cells. A. baumannii lipid A
was prepared using an ammonium hydroxide-isobutyric acid-based ex-
traction procedure (18). Briefly, approximately 10 mg of lyophilized ma-
terial derived from an overnight culture was resuspended in 400 l of
isobutyric acid and 1 M ammonium hydroxide (5:3, vol/vol) and incu-
bated at 100°C for 1 h. After cooling, individual samples were centrifuged
for 15 min at 2,000  g, and supernatants were collected and diluted 1:1
(vol/vol) with endotoxin-free water. The samples were subsequently fro-
zen and lyophilized overnight. The resultant powdered material was then
washed twice with 1 ml of methanol, and the insoluble lipid A was ex-
tracted in 200 l of a mixture of chloroform, methanol, and water (3:1:
0.25 [vol/vol/vol]). One microliter of this extract was then spotted onto a
matrix-assisted laser desorption ionization (MALDI) plate followed by 1
l of norharmane matrix (Sigma) and air dried.
Fatty acid analysis. LPS fatty acids were converted to fatty acid methyl
esters and analyzed by gas chromatography (GC) as previously described
(19, 20). Briefly, 10 mg of lyophilized bacterial cell pellet was incubated at
70°C for 1 h in 500 l of 90% phenol and 500 l of water. Samples were
then cooled on ice for 5 min and centrifuged at 10,000 rpm for 10 min. The
aqueous layer was collected, and 500 l of water was added to the lower
(organic) layer and incubated again. This process was repeated twice
more, and all aqueous layers were pooled. Two milliliters of ethyl ether
was added to the harvested aqueous layers. This mixture was then vor-
texed and centrifuged at 3,000 rpm for 5 min. The lower (organic) phase
was then collected, and 2 ml of ether was added back to the remaining
aqueous phase. This process was carried out twice more. The collected
organic layer was then frozen and lyophilized overnight. LPS fatty acids
were converted to fatty methyl esters, in the presence of 10 g pentade-
canoic acid (Sigma) as an internal standard, with 2 M methanolic HCl
(Alltech, Lexington, KY) at 90°C for 18 h.
Mass spectrometry. (i) ESI-LTQ-FT MS. Lipid A was analyzed by
electrospray ionization-linear ion trap-Fourier transform ion cyclotron
resonance mass spectrometry (ESI-LTQ-FT MS) in the negative ion mode
on an LTQ-FT linear ion trap Fourier transform ion cyclotron resonance
mass spectrometer (Thermo Scientific, San Jose, CA). Samples were di-
luted to 1 mg/ml in chloroform-methanol (1:1, vol/vol) and infused at a
rate of 1.0 ml/min via a fused silica capillary (inner diameter, 75 m; outer
diameter, 360 m) with a 30-m spray tip (New Objective, Woburn,
MA). Instrument calibration and tuning parameters were optimized us-
ing a solution of Ultramark 1621 (Lancaster Pharmaceuticals, PA) in both
positive and negative ion modes. For experiments acquired in the ion
FIG 1 Modification of the lipid A component of lipopolysaccharide by positively charged residues, including ethanolamine, aminoarabinose, and glucosamine,
alters resistance to CAMPs. (A) Salmonella Typhimurium; (B) Francisella tularensis.
Pelletier et al.
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cyclotron resonance (ICR) cell, the mass resolving power was set to
100,000 and ion populations were held constant by automatic gain con-
trol at 1.0  106 for mass spectrum (MS) acquisition and at 5.0  105 for
tandem mass spectra (MSn), respectively. For tandem mass spectra, the
precursor ion selection window was set to 4 to 8 Da and the collision
energy was set to 30% on the instrument scale. The collision-induced
dissociation (CID) MSn analyses in the linear ion trap were acquired with
an ion population of 1.0  104 and maximum fill time of 200 ms. The
subsequent MS2, MS3, and MS4 events had an isolation window of 2 Da
with a collision energy of 25%. All spectra were acquired over a time
period of 1 to 2 min and averaged. Typically, MS events were mass ana-
lyzed in the ICR cell and MS2, MS3, and MS4 events were mass analyzed in
the LTQ. Infrared multiphoton dissociation (IRMPD) MS2 events were
acquired in the ICR cell using detection parameters similar to the ones
described above. Precursor ions were irradiated by IR photons produced
by a CO2 laser (Synrad Firestar Series V20, model FSV20SFB 75 W [10.2 to
10.8 m]) with pulse durations of 20 to 100 ms and pulse power of 20 to
80%. Data were acquired and processed using Xcalibur, version 1.4
(Thermo Scientific), utilizing 7-point Gaussian smoothing.
(ii) MALDI-TOF MS. Lipid A was analyzed on an AutoFlex Speed
MALDI-time of flight (TOF) mass spectrometer (Bruker Daltonics, Bil-
lerica, MA). Samples were dissolved in 10 l of norharmane (20 mg/ml) in
chloroform-methanol-water, 4:4:1 (vol/vol/vol), and 0.5 l of sample was
analyzed and spotted directly onto the MALDI target plate. Data were
acquired in reflectron negative and positive modes with a Smartbeam
laser with a 1-kHz repetition rate, and up to 4,000 shots were accumulated
for each spectrum. Instrument calibration and all other tuning parameters
were optimized using Agilent Tuning mix (Agilent Technologies, Foster
City, CA). Data were acquired and processed using flexControl and flex-
Analysis version 3.3 (Bruker Daltonics).
Amino sugar assay chemicals and reagent. Glucosamine hydrochlo-
ride, N-acetylglucosamine, 2-amino-2-methyl-1, and 3-propanediol were
from Sigma. 2-Galactoseamine hydrochloride was from Calbiochem
(Gibbstown, NJ). The derivatizing reagent, 6-aminoquinoyl-N-hydroxy-
succinimidyl carbamate (AQHSC), was purchased from Waters (AccQ-
Fluor; Milford, MA). Trifluoroacetic acid (TFA) was from Sigma. All
high-pressure liquid chromatography (HPLC) solvents and buffers were
of analytical grade.
LPS purification and lipid A isolation. LPS was isolated using a small-
scale isolation method for mass spectrometry analysis as described previ-
ously (21). Lipid A was isolated using mild-acid hydrolysis as previously
described (17).
Sample preparation. Standards and biological samples were prepared
as described previously (22). Briefly, standards were dissolved in 200 l
1.0 M TFA, vortexed, and heated at 90°C for 30 min or 24 h. The samples
were then frozen, lyophilized, and dissolved in 50 l 0.2 M borate buffer,
pH 8.8, prior to the addition of 50 l of 1 mg/ml AccQ-Tag derivatizing
reagent in acetonitrile. The samples were vortexed, incubated at room
temperature for 15 to 30 min, and then evaporated to dryness under
nitrogen. Derivatized samples were reconstituted in 100 l of distilled
water, vortexed, and transferred to injection vials for analysis. For analysis
of biological samples, 10 g of lipid A isolated from individual prepara-
tions was used. They were then derivatized by the same procedure as the
standards as described above.
Instrumentation. All analyses were performed on a liquid chroma-
tography tandem mass spectrometry (LC-MS/MS) platform.
Liquid chromatography. The analytes were separated using a Develo-
sil 5u RP-Aqueous C-30 column (150 by 2.1 mm) (Phenomenex, Tor-
rance, CA) using a 10 mM ammonium acetate (pH 7.5)–acetonitrile
(ACN) gradient. The initial organic was 2.0% ACN and increased to 5.0%
at 0.5 min. Thereafter, there was a linear increase to 10% ACN at 6.5 min
and then to 20% ACN at 17 min. The ACN was increased to 80% for a
1-min washout and then dropped back to the initial (2%) ACN and re-
equilibrated for 8.0 min. The flow was 0.4 ml throughout the run, the
temperature was 25°C, and the run time was 30 min. Eluent before 4.5 and
after 16 min was diverted from the mass spectrometer.
Mass spectrometry data. All mass spectra were acquired using posi-
tive electrospray ionization mode. Selected reaction monitoring (SRM)
studies were performed on a Thermo TSQ Quantum Ultra Triple Stage
quadrupole mass spectrometer. The scans of the derivatives universally
showed an intense signal at (analyte MW  170  H) with minimal
fragmentation. This is equivalent to m/z 350 (GalA and GluA). The ob-
served signals were consistent with the formation of the N-quinoyl-N=-
aminosaccharide urea as the derivative. The SRM transitions for both
GalN and GlcN were 350-171. GalN and GlcN had the same transition and
were differentiated by chromatographic retention times. The ionization
conditions used in SRM were as follows: spray voltage, 3,000 V; capillary
temperature, 40°C; capillary offset, 10 V; vaporizer temperature, 40°C;
sheath gas pressure, 5 lb/in2; auxiliary gas pressure, 5 lb/in2; ion sweep gas
pressure, 0.5 lb/in2.
RESULTS
Lipid A structure from a laboratory-adapted colistin-resistant
strain of A. baumannii. As colistin-resistant strains of A. bau-
mannii are an increasing problem in clinical settings, we hy-
pothesized that generating strains with increased resistance to
colistin would result in lipid A modifications specific to these
colistin-resistant strains. To determine the presence of colis-
tin-induced lipid A modifications resulting in the A. baumannii
MAC204 laboratory strain, we generated an A. baumannii
colistin-resistant laboratory-adapted strain. We now describe
the structural determination of the chemical structure of lipid
A from A. baumannii LPS using MALDI-TOF MS along with
ESI MS and MSn mass spectra. Particular emphasis will be de-
voted to determining acyl chain positioning, phosphoethano-
lamine (pEtN) addition, and glycan (GalN) modification (both
location and identification).
After overnight growth at 37°C in rich medium (LB), lipid A
was isolated from the colistin-resistant A. baumannii strain
MAC204 and its colistin-susceptible parent strain ATCC 17978
and analyzed by MALDI-TOF mass spectrometry in the negative
ion mode. Analysis of lipid A isolated from strain ATCC 17978
(Fig. 2A) showed that an abundant [M-H] ion was at m/z 1,910,
which was tentatively identified as a singly deprotonated lipid A
structure that contained two phosphate groups and seven acyl
chains (i.e., diphosphoryl hepta-acylated lipid A). Other abun-
dant [M-H] ions were associated with different acylation or
phosphorylation configurations. Of note, ions at m/z 2,033 and
2,071 were absent from these spectra. In contrast, lipid A isolated
from the colistin-resistant strain MAC204 (Fig. 2B) displayed not
only the [M-H] at m/z 1,910 but also ions at m/z 2,033 and m/z
2,071, consistent with pEtN and hexosamine additions, respec-
tively. In this strain, we also saw an [M-H] ion at m/z 2,216,
corresponding to a pEtN plus a hexosamine addition along with a
sodium adduct. Previous reports have shown A. baumannii lipid A
to be modified with pEtN, but to the best of our knowledge, hexo-
samine has not been previously reported for colistin-resistant A.
baumannii strains.
To definitively identify the lipid A additions detected by
MALDI-TOF MS analysis, we performed high-order negative ion
mode ESI LTQ-FT mass spectrometry of lipid A isolated from A.
baumannii strain MAC204, with results shown in Fig. 2C. The
most abundant ion at m/z 1,910 from Fig. 2C corresponded to the
structure identified by MALDI-TOF MS. Hereinafter, all initial
structure characterization using precursor ion m/z values were
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supported by elemental composition based on accurate mass mea-
surements and literature when available. Several other prominent
singly charged ions were recorded at m/z values greater than 2,000
Da. These ions corresponded to lipid A structures containing the
addition of pEtN (m/z 2,033), that of hexosamine (m/z 2,071), and
both modifications (m/z 2,194).
Determination of acyl chain positioning of lipid A isolated
from A. baumannii LPS using tandem mass spectrometry. Tan-
dem mass spectrometric experiments were carried out to confirm
the location of the seven fatty acids. Initial characterization based
on elemental composition from accurate mass measurements of
the hepta-acylated lipid A anion, m/z 1,910, revealed the presence
FIG 2 Negative ion mode MALDI-TOF MS mass spectra of A. baumannii ATCC 17978 (A) and MAC204 (B). (C) Negative ion mode ESI FT-ICR mass spectrum
of lipid A isolated from A. baumannii LPS. All ions are singly charged. The inset structure is a proposed configuration for bis-phosphoryl, hepta-acylated lipid A
from A. baumannii. pEtN, phosphoethanolamine; C12, lauric acid; C12(3-OH), 3-hydroxy lauric acid; HPO3, phosphate; C-1, C-1 position phosphate houses the
modification; C-4=, C-4= position phosphate houses the modification.
Pelletier et al.
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of four primary fatty acids, i.e., two 3-hydroxylauric acid [C12(3-
OH)] acyl chains and two 3-hydroxymyristic acid [C14(3-OH)]
acyl chains and of three secondary fatty acids, i.e., one C12(3-OH)
acyl chain and two lauric acid (C12) acyl chains. A similar acylation
pattern has been reported previously, yet conclusive evidence for
assignment of each fatty acid to a specific location was not deter-
mined (22, 23).
In order to determine the positioning of the seven fatty acids,
we conducted a series of tandem mass spectrometric experiments
aimed at highlighting diagnostic cross-ring and glycosidic cleav-
age product ions that provided evidence for pinpointing acyl
chain positions. Detailed descriptions of the tandem mass spectra
(MSn) experiments, the corresponding rationale for fatty acid as-
signment, and the MSn spectra are given in Fig. S1 and S2 in the
supplemental material. The hepta-acylated lipid A structure was
determined to have the following configuration: the C-2 position
contained a primary amide-linked C14(3-OH) and a secondary
ester-linked C12, the C-3 position contained a primary ester-
linked C12(3-OH), the C-2= position contained a primary amide-
linked C14(3-OH) and a secondary ester-linked C12(3-OH), and
the C-3= position contained a primary ester-linked C12(3-OH)
and a secondary ester-linked C12. The acyl chain configuration as
outlined above held true for all hepta-acylated lipid A extracted
from A. baumannii. The proposed structure of hepta-acylated
lipid A extracted from A. baumannii is shown in the inset in Fig. 2.
Finally, to determine the amount of total fatty acids in lipid A,
A. baumannii strain ATCC_ C2B was grown at 37°C overnight,
lipid A was extracted, and the fatty acids were analyzed by capillary
gas chromatography using flame ionization detection (FID). As
shown in Fig. 3, this analysis yielded percentages of total fatty acids
of 24.6%  0.7% C12, 9.3%  0.1% 2-OH C12, 29.9%  0.1%
3-OH C12, and 36.2%  0.5% 3-OH C14, confirming the struc-
tural characterization by MS above.
Identification and localization of pEtN addition to lipid A
isolated from A. baumannii LPS using tandem mass spectrom-
etry. Tandem mass spectrometric experiments on the precursor
ion at m/z 2,033, which corresponded to the addition of a pEtN
substituent to hepta-acylated lipid A, were carried out in turn to
correctly identify and localize the pEtN modification. Accurate
mass measurement of the hepta-acylated structure (m/z 1,910)
plus the 123 mass unit modification precursor ion at m/z 2,033
revealed the elemental composition of the 123 mass unit
modification to be C2H6NPO3, which corresponded to pEtN
(C2H6NPO3; accurate mass, 123.0085; experimental mass,
123.0161; 7.6 millimass units [mmu]). The pEtN modification has
been reported previously, yet evidence for localizing the pEtN
group was suggestive (22, 23). We determined the location of the
pEtN modification via a series of tandem mass spectrometric ex-
periments aimed at highlighting diagnostic product ions that pro-
vided convincing evidence for pEtN localization.
Gas phase dissociation of the precursor ion at m/z 2,033 result-
ing in the generation of an MS2 mass spectrum is highlighted in
Fig. S3 in the supplemental material. The overwhelming dissocia-
tion pathway from the precursor ion at m/z 2,033 involved the
neutral loss of the pEtN group at m/z 1,910. The ion at m/z 1,910
corresponded to diphosphoryl hepta-acylated lipid A (see above
for acyl chain assignments). In addition to the abundant ion at m/z
1,910, a series of more modestly abundant product ions resulting
from competitive and consecutive neutral loss(es) from pEtN,
fatty acids, and phosphate were present. These ions provided in-
sight regarding the acyl chain and phosphate configuration; how-
ever, they did not yield conclusive evidence for pEtN assignment.
pEtN localization was achieved via examination of product ions
resulting from cross-ring and glycosidic cleavages.
Diagnostic glycosidic and cross-ring product ions allowed us
to assign the pEtN modification to both the reducing and the
nonreducing ends of the lipid A disaccharide backbone. The MSn
spectra and detailed analysis are shown in Fig. S3 in the supple-
mental material. Moreover, the pEtN group was found to be at-
tached to the lipid A backbone via a phosphodiester bond at either
the C-4= monophosphate or the C-1 monophosphate position. Of
particular note, the phosphorylation pattern for lipid A extracted
from A. baumannii LPS was determined to be both bisphosphor-
ylated and pyrophosphorylated (see Fig. S3 in the supplemental
material). At this level of MS analysis, we did not observe pEtN
attached directly to a pyrophosphate group or pEtN attached
without linkage to the C-4= or C-1 monophosphate group. The
presence of pyrophosphate in the structure corresponding to m/z
2,033 was confirmed in the IRMPD (infrared multiphoton disas-
sociation) MS2 mass spectrum of the ion at m/z 2,033 (data not
shown). A previous report (24) estimated the abundance of pyro-
phosphorylated lipid A extracted from Yersinia pestis LPS to be
near 5%. Equally apparent from this report was the vast majority
(95%) of diphosphorylated lipid A with a bisphosphorylated
configuration. Therefore, assuming that A. baumannii lipid A is
predominately composed of bisphosphate and due to the inability
to sufficiently characterize pyrophosphorylated lipid A from A.
baumannii, we focused our efforts on characterizing the PEtN
modification in the context of bisphosphorylated A. baumannii
lipid A.
Localization of the glycan addition to lipid A isolated from A.
baumannii LPS using tandem mass spectrometry. Tandem mass
spectrometric experiments on the precursor ion at m/z 2,071,
which corresponded to the addition of a hexosamine group to
hepta-acylated lipid A, were carried out in order to localize the
glycan modification. Accurate mass measurement of the hepta-
acylated plus the 161 mass unit modification precursor ion at m/z
2,071 revealed the elemental composition of the 161 mass unit
modification to be a hexosamine group (C6H11NO4; accurate
mass, 161.0688; experimental mass, 161.0598; mass difference, 9.0
mmu). The glycan modification has not been reported previously.
A series of tandem mass spectrometric experiments were con-
ducted to highlight diagnostic product ions that provided con-
vincing evidence for localizing the glycan modification.
Gas phase dissociation of the precursor ion at m/z 2,071 result-
ing in the generation of an MS2 mass spectrum is highlighted in
FIG 3 Fatty acid analysis via GC-FID displayed via percentage of fatty acid
present to total fatty acids.
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Fig. S4 in the supplemental material. The overwhelming dissocia-
tion pathway from the precursor ion at m/z 2,071 involved the
neutral loss of the hexosamine group at m/z 1,910. The ion at m/z
1,910 corresponded to diphosphoryl hepta-acylated lipid A (see
above for phosphate and acyl chain assignments). Similar to struc-
ture determination as described above, the glycan localization was
achieved via examination of diagnostic product ions resulting
from cross-ring and glycosidic cleavages.
We identified several glycosidic cleavages that allowed us to
assign the glycan modification to the reducing end of the lipid A
disaccharide (see Fig. S3 in the supplemental material). Further-
more, the glycan group was found to be attached to the lipid A
backbone via a phosphodiester bond at the C-1 monophosphate
position. At this level of MS sophistication, we did not observe the
glycan attached directly to a pyrophosphate group or attached
without linkage to the C-1 monophosphate group. Once again, it
was assumed, as outlined previously, that A. baumannii lipid A is
predominately composed of bisphosphate lipid A, and therefore
we focused our efforts on characterizing the hexosamine modifi-
cation in context with bisphosphorylated A. baumannii lipid A.
Assignment of the phosphoethanolamine (pEtN) and glycan
modifications to lipid A isolated from A. baumannii LPS using
tandem mass spectrometry. Tandem mass spectrometric experi-
ments on the precursor ion at m/z 2,194, which corresponded to
the addition of both pEtN and hexosamine substituents to hepta-
acylated lipid A were performed to correctly identify and localize
these substituents. Accurate mass measurement of the hepta-acy-
lated plus the 123 and 161 mass unit modifications at m/z 2,194
revealed the elemental composition of the 123 mass unit modifi-
cation to be pEtN (C2H6NPO3; accurate mass, 123.0085; experi-
mental mass, 123.0001; 8.4 mmu) and the 161 mass unit modifi-
cation to be hexosamine (C6H11NO4; accurate mass, 161.0688;
experimental mass, 161.0620; mass difference, 6.8 mmu). The
combined pEtN and hexosamine modifications have not been re-
ported previously.
Gas-phase dissociation of the precursor ion at m/z 2,194 result-
ing in the generation of a MS2 mass spectrum is highlighted in Fig.
S5 in the supplemental material. The overwhelming dissociation
pathway from the precursor ion at m/z 2,194 involved the neutral
loss of both the pEtN and the hexosamine groups at m/z 1,910. The
ion at m/z 1,910 corresponded to diphosphoryl hepta-acylated
lipid A (without pEtN and hexosamine). pEtN and hexosamine
localization was achieved via examination of product ions result-
ing from cross-ring and glycosidic cleavages.
Diagnostic product ions (see Fig. S4 and the supplemental ma-
terial for detailed analysis) allowed us to confidently assign the
pEtN modification to the nonreducing end and the hexosamine
modification to the reducing end of the lipid A disaccharide back-
bone. Moreover, both modifications were found to be attached to
the lipid A backbone via a phosphodiester bond at the C-4= mono-
phosphate position for pEtN and at the C-1 monophosphate po-
sition for hexosamine. The structure assignment was in context to
the predominant bisphosphate lipid A configuration.
Identification of the hexosamine modification to lipid A ex-
tracted from LPS of an A. baumannii clinical isolate via LC-MS/
MS. In order to confirm the identity of the hexosamine sugar
modification to A. baumannii lipid A, we utilized an LC-MS/MS
platform previously developed in our laboratory for detection and
quantitation of amino sugars isolated from lipid A in Francisella
novicida (25–27). This study demonstrated the detection of the
GalN modification to lipid A. The GalN modification resulted in
increased resistance to polymyxin B. For this study, we used the
Colr clinical isolate 1508, which is highly resistant to colistin (MIC
[MIC], 24 g/ml by Etest) to assay for the presence of amino
sugars (Table 1).
We hypothesized that the presence of GalN, along with pEtN,
could be responsible for this phenotype. Indeed, as shown in Fig.
4, we provide evidence for the addition of GalN to A baumannii
lipid A. Figure 5A depicts an extracted ion chromatogram for
glucosamine (GlcN) and GalN standards. Four peaks are observed
and corresponded to two isomers each for GlcN and GalN. Figure
5B corresponds to the Colr clinical isolate 1508.
Analysis of the extracted ion chromatogram for isolate 1508
(Fig. 4B) clearly demonstrates that the hexosamine modification
was GalN. The percent relative abundance of lipid A modified
with the GalN of clinical isolate 1508 was approximately 30%,
showing a substantial presence of this substituent.
Lipid A profiles of A. baumannii clinical strains. Colistin re-
sistance in A. baumannii has been linked to pEtN modification of
lipid A. To determine if these modifications are relevant and de-
tectable in multiple patients’ samples, we extracted lipid A from
cross-sectional samples of three individual Cols clinical strains,
collected from patients before colistin therapy at the University of
Pittsburgh Medical Center. After growth at 37°C in rich medium
(LB), lipid A was isolated and analyzed by MALDI-TOF mass
spectrometry.
TABLE 1 Summary of lipid A structural modifications observed by
MALDI-TOF in A. baumannii clinical isolates and MIC data
Clinical
strain
Sample
source
Colistin Etest
MIC (g/ml)
Colistin
therapy
pEtN
addition
GalN
addition
1494 BALa 0.06 No  
1508 Sputum 24 Yes  
2382 BAL 0.02 No  
2384 BAL 1.5 Yes  
2949 BAL 1 No  
2949A BAL 48 Yes  
a BAL, bronchoalveolar lavage fluid.
FIG 4 Proposed structure for lipid A extracted from A. baumannii LPS with
both the pEtN and GalN modifications.
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Analysis of lipid A isolated from our cross-sectional samples of
Cols clinical strains (Fig. 6A, C, and E) showed that the most
abundant [M-H] ion was at m/z 1,910. Also of note, ions at m/z
values corresponding to pEtN (m/z 2,033) and GalN (m/z 2,071)
were absent from these spectra. The [M-H] ion at m/z 1,910
corresponding to a diphosphorylated hepta-acylated lipid A was
observed in all mass spectra (Fig. 6). In contrast, lipid A isolated
from Colr clinical strains from the same patients after colistin
therapy (Fig. 6B, D, and F) displayed not only the abundant [M-
H] at m/z 1,910 but also ions at m/z 2,033 and m/z 2,071, consis-
tent with pEtN and GalN additions, respectively. While A. bau-
mannii lipid A modified with pEtN has been reported in previous
studies, GalN has not been previously reported for A. baumannii
clinical strains.
All Colr clinical strains (Table 1) contained the [M-H] ions
corresponding to pEtN and GalN modifications. To corroborate
the detection of the GalN modifications observed in the negative
ion mode, we performed positive ion mode [M-H] MALDI-
TOF MS using lipid A isolated from the same Colr clinical strains
shown in Fig. 6B, D, and F (refer to the “ mode” insets in these
panels). We hypothesized that the GalN moiety may be easier to
detect in positive mode. The resulting spectra showed detection of
GalN (m/z 2,073) in these samples due to the overall difference in
net charge in positive mode. GalN should have an m/z of 2073 in
positive ion mode rather than 2,071, as the analyte is doubly pro-
tonated. Also detected is a peak at m/z 2,087 that is a methylated
variant of the GalN peak detected at m/z 2,073. There were also
novel peaks detected in positive mode not seen in the negative
mode analysis, and these ions are currently being defined. These
results clearly demonstrate that lipid A isolated from these clinical
strains contain lipid A structures that included the addition of pEtN
and GalN substituents in response to colistin treatment. In summary,
we show evidence that A. baumannii Colr clinical isolates show the
same lipid A modifications as in the Colr laboratory-adapted strain
and using both negative- and positive-mode MALDI-TOF MS.
DISCUSSION
In the setting of multidrug-resistant A. baumannii, tigecycline and
especially colistin are the agents of last resort to combat this prob-
lematic pathogen. Despite previous reports of toxicity concerns,
colistin has reemerged as the agent of choice to treat severe sys-
temic and pulmonary A. baumannii infections (2, 28–30). Colistin
resistance has been linked to modifications of the lipid A of the
LPS moiety from many bacterial species, including A. baumannii
strains (10, 11). Indeed, in this study we deduced the lipid A struc-
ture from LPS from the Colr A. baumannii MAC204 laboratory-
adapted strain, and the resulting lipid A structure contains impor-
tant modifications for colistin resistance. Using electrospray
ionization (ESI) tandem mass spectrometry, we demonstrate that
lipid A is hepta-acylated with secondary C12 and C14 acyl chains,
bis- and pyrophosphorylated, along with a novel hexosamine ad-
dition shown to be GalN at the 1-phosphate position and a pEtN
addition at the 4= phosphate position. Using GC-FID analysis, we
were able to quantify the fatty acid content of a Colr A. baumannii
isolate. Finally, we used a set of clinical isolates from the same
patient, showing that the modifications seen in our structural
analysis from the MAC204 Colr laboratory-adapted strain are
identical to the lipid A modifications in the Colr clinical isolates.
The ability of these modifications to translate to clinical strains is
important, as colistin is one of the last lines of defense for treat-
FIG 5 LC-MS/MS selected reaction monitoring (SRM)-extracted ion chromatogram for galactosamine standard (A) and lipid A extracted from Colr A.
baumannii 1508 LPS (B). Standard concentrations used were 1, 7, and 25 ng/ml.
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ment against MDR A. baumannii strains. Thus, these important
lipid A modifications could play a critical role in colistin resistance
and subsequent patient outcome.
Lipid A structural analysis from the genus Acinetobacter was
first delineated from the A. radioresistens strain S13 and showed
that the major lipid A structure was a di-phosphoryl hepta-acy-
lated structure with an m/z of 1,838.18 (31). Recent work has
shown that modification of lipid A is a strategy employed not only
in A. baumannii strains but in many other Gram-negative bacte-
ria. Recent reports have shown Shigella flexneri lipid A to be mod-
ified by pEtN groups and involved in resistance to extreme acidity
(32). Loss of pEtN addition in lptA null strains (lptA encodes the
pEtN transferase for the 4= position of lipid A) of Neisseria gonor-
rhoeae modulates resistance to complement killing and poly-
myxin resistance (33). Neisseria commensal strains that lack lptA
and pEtN addition to lipid A were more susceptible to polymyxin
B and showed an increased inflammatory response via TLR4 (34).
In the flagellated bacterium Campylobacter jejuni, lipid A is
decorated with pEtN mediated by EptC, which serves a dual role as
a pEtN transferase modulating CAMP resistance and as a modifier
of the flagellar rod protein FlgG (35, 36). Helicobacter pylori mod-
ifies its lipid A in a two-step process whereby the removal of the
FIG 6 Negative ion mode MALDI-TOF mass spectra of A. baumannii clinical strains matched isolates Cols 1494 and Colr 1508 (A and B), matched isolates Cols
2382 and Colr 2384 (C and D), and matched isolates Cols 2949 and Colr 2949A (E and F). Positive ion mode MALDI-TOF mass spectra are shown in insets in
panels B, D, and F. At m/z 2,069 is the GalN ion detected in positive mode, corresponding to the m/z 2,071 GalN ion detected in negative mode.
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1-phosphate group by a lipid A phosphatase LpxE is followed by
the addition of a pEtN residue catalyzed by EptA, resulting in
increased resistance to polymyxin (37).
PmrA-LpxT-dependent pEtN modification of lipid A in Sal-
monella enterica serovar Typhimurium and Escherichia coli strains
has been well documented (38) as well as a PmrC-dependent pEtN
addition to the lipid A of E. coli O157:H7 (39). Surprisingly, the
canine pathogen Capnocytophaga canimorsus and plant pathogens
Xanthomonas campestris and Xanthomonas axanopodis have lipid
A modified with pEtN, also altering their innate immune re-
sponses and disease manifestations. Thus, modification of lipid A
by pEtN as a means to evade the effects of antimicrobial agents by
altering the electrostatic charge on the bacterial membrane is
prevalent (40, 41).
Additionally we have also shown a novel GalN addition to a
Colr laboratory-adapted strain and Colr clinical strains as shown
by high-order MS along with LC-MS/MS. This modification is
also seen on the lipid A from Francisella novicida as published
previously by our laboratory (25, 27) and others in the Francisella
field (42, 43). In the setting of F. novicida, the enzyme FlmK adds
a GalN and a mannose residue to the 1 and 4= positions of lipid A
whereas the FlmF2 enzyme is responsible for the addition of the
GalN residue. GalN additions have also been shown to modulate
resistance to antimicrobial agents (25), demonstrating the impor-
tance of elucidating this novel addition to the A. baumannii lipid A
structure. In this context, a GalN modification could play a role in
colistin resistance similar to that of aminoarabinose modifica-
tions, which have been shown to modulate antimicrobial resis-
tance by altering the electrostatic charge on the bacterial mem-
brane (along with pEtN modifications). Thus, these lipid A
modifications have clinical ramifications in the setting of A. bau-
mannii treatment.
Of interest is that these observations indicate that the presence
or absence of pEtN and GalN on lipid A extracted from A. bau-
mannii isolates may be used as novel biomarkers to be exploited
for diagnosis of colistin resistance. Currently, the reliability and
accuracy of susceptibility testing methods such as disk diffusion
and Etest are compromised by poor agar diffusion of colistin due
to its molecular size and poor concordance at low concentration,
respectively (44–46). Therefore, further confirmation with differ-
ent methods is required. Taken together, the potential to deter-
mine the presence or absence of modified lipid A with pEtN or
GalN on bacterial clinical isolates by mass spectrometry could
serve as an alternative diagnostic test to predict the resistance of
bacteria to polymyxins and potentially guide therapeutic choices
that will improve clinical outcomes.
ACKNOWLEDGMENTS
Y.D. was supported in part by a career development award from the NIH
(K22AI080584). D.V.Z is funded via grants from the Military Infectious
Diseases Research Program (MIDRP) and the Defense Medical Research
and Development Program (DMRDP). This material is based upon work
supported by, or in part by, the U.S. Army Research Laboratory and the
U.S. Army Research Office under Contract/Grant no. W911NF-11-1-
0274 to K.R.O.H and R.K.E.
The findings and opinions expressed herein belong to the authors and
do not necessarily reflect the official views of the WRAIR, the U.S. Army,
or the Department of Defense.
REFERENCES
1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA.
2007. Global challenge of multidrug-resistant Acinetobacter baumannii.
Antimicrob. Agents Chemother. 51:3471–3484.
2. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK,
Peterson J, Davies TA. 2012. Multidrug resistance among Acinetobacter
spp. in the USA and activity profile of key agents: results from CAPITAL
Surveillance 2010. Diagn. Microbiol. Infect. Dis. 73:267–270.
3. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain
J, Craft D, Riddell S, Lindler L, Mancuso J, Milstrey E, Bautista CT,
Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G,
Petersen K, Endy T, Petruccelli B. 2007. An outbreak of multidrug-
resistant Acinetobacter baumannii-calcoaceticus complex infection in the
US military health care system associated with military operations in Iraq.
Clin. Infect. Dis. 44:1577–1584.
4. Sebeny PJ, Riddle MS, Petersen K. 2008. Acinetobacter baumannii skin
and soft-tissue infection associated with war trauma. Clin. Infect. Dis.
47:444 – 449.
5. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST,
Rollin PE, Towner JS, Shieh WJ, Batten B, Sealy TK, Carrillo C, Moran
KE, Bracht AJ, Mayr GA, Sirios-Cruz M, Catbagan DP, Lautner EA,
Ksiazek TG, White WR, McIntosh MT. 2009. Discovery of swine as a
host for the Reston ebolavirus. Science 325:204 –206.
6. Whitman TJ, Qasba SS, Timpone JG, Babel BS, Kasper MR, English JF,
Sanders JW, Hujer KM, Hujer AM, Endimiani A, Eshoo MW, Bonomo
RA. 2008. Occupational transmission of Acinetobacter baumannii from a
United States serviceman wounded in Iraq to a health care worker. Clin.
Infect. Dis. 47:439 – 443.
7. Basheer SM, Guiso N, Tirsoaga A, Caroff M, Novikov A. 2011. Struc-
tural modifications occurring in lipid A of Bordetella bronchiseptica clini-
cal isolates as demonstrated by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 25:
1075–1081.
8. Llobet E, Campos MA, Gimenez P, Moranta D, Bengoechea JA. 2011.
Analysis of the networks controlling the antimicrobial-peptide-
dependent induction of Klebsiella pneumoniae virulence factors. Infect.
Immun. 79:3718 –3732.
9. Moskowitz SM, Ernst RK, Miller SI. 2004. PmrAB, a two-component
regulatory system of Pseudomonas aeruginosa that modulates resistance to
cationic antimicrobial peptides and addition of aminoarabinose to lipid A.
J. Bacteriol. 186:575–579.
10. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M,
Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phos-
phoethanolamine modification of lipid A in colistin-resistant variants of
Acinetobacter baumannii mediated by the pmrAB two-component regula-
tory system. Antimicrob. Agents Chemother. 55:3370 –3379.
11. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock
RE. 2011. The pmrCAB operon mediates polymyxin resistance in Acineto-
bacter baumannii ATCC 17978 and clinical isolates through phosphoetha-
nolamine modification of lipid A. Antimicrob. Agents Chemother. 55:
3743–3751.
12. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR,
Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter
baumannii associated with mutations in the PmrAB two-component sys-
tem. Antimicrob. Agents Chemother. 53:3628 –3634.
13. Westphal OJK. 1965. Bacterial lipopolysaccharides: extraction with phe-
nol–water and further applications of the procedure. Methods Carbohydr.
Chem. 43:83–91.
14. Fischer W, Koch HU, Haas R. 1983. Improved preparation of lipo-
teichoic acids. Eur. J. Biochem. 133:523–530.
15. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the
isolation and purification of total lipides from animal tissues. J. Biol.
Chem. 226:497–509.
16. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. 2000. Cutting edge:
repurification of lipopolysaccharide eliminates signaling through both
human and murine toll-like receptor 2. J. Immunol. 165:618 – 622.
17. Caroff M, Tacken A, Szabo L. 1988. Detergent-accelerated hydrolysis of
bacterial endotoxins and determination of the anomeric configuration of
the glycosyl phosphate present in the “isolated lipid A” fragment of the
Bordetella pertussis endotoxin. Carbohydr. Res. 175:273–282.
18. El Hamidi A, Tirsoaga A, Novikov A, Hussein A, Caroff M. 2005.
LPS Modification Involved in Colistin Resistance
October 2013 Volume 57 Number 10 aac.asm.org 4839
 
Microextraction of bacterial lipid A: easy and rapid method for mass spec-
trometric characterization. J. Lipid Res. 46:1773–1778.
19. Darveau RP, Cunningham MD, Bailey T, Seachord C, Ratcliffe K,
Bainbridge B, Dietsch M, Page RC, Aruffo A. 1995. Ability of bacteria
associated with chronic inflammatory disease to stimulate E-selectin ex-
pression and promote neutrophil adhesion. Infect. Immun. 63:1311–
1317.
20. Somerville JE, Jr, Cassiano L, Bainbridge B, Cunningham MD, Darveau
RP. 1996. A novel Escherichia coli lipid A mutant that produces an antiin-
flammatory lipopolysaccharide. J. Clin. Invest. 97:359 –365.
21. Yi EC, Hackett M. 2000. Rapid isolation method for lipopolysaccharide
and lipid A from gram-negative bacteria. Analyst 125:651– 656.
22. Kussak A, Weintraub A. 2002. Quadrupole ion-trap mass spectrometry
to locate fatty acids on lipid A from Gram-negative bacteria. Anal.
Biochem. 307:131–137.
23. Boue SM, Cole RB. 2000. Confirmation of the structure of lipid A from
Enterobacter agglomerans by electrospray ionization tandem mass spec-
trometry. J. Mass Spectrom. 35:361–368.
24. Chan S, Reinhold VN. 1994. Detailed structural characterization of lipid
A: electrospray ionization coupled with tandem mass spectrometry. Anal.
Biochem. 218:63–73.
25. Kanistanon D, Hajjar AM, Pelletier MR, Gallagher LA, Kalhorn T,
Shaffer SA, Goodlett DR, Rohmer L, Brittnacher MJ, Skerrett SJ, Ernst
RK. 2008. A Francisella mutant in lipid A carbohydrate modification elic-
its protective immunity. PLoS Pathog. 4:e24. doi:10.1371/journal.ppat
.0040024.
26. Domon B, Costello CE. 1988. Systematic nomenclature for carbohydrate
fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconju-
gate 5:397– 409.
27. Kalhorn TF, Kiavand A, Cohen IE, Nelson AK, Ernst RK. 2009. A
sensitive liquid chromatography/mass spectrometry-based assay for
quantitation of amino-containing moieties in lipid A. Rapid Commun.
Mass Spectrom. 23:433– 442.
28. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of
Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial
strategies. J. Antimicrob. Chemother. 67:1607–1615.
29. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin
and polymyxin B against a worldwide collection of Gram-negative patho-
gens: results from the SENTRY Antimicrobial Surveillance Program
(2006-09). J. Antimicrob. Chemother. 66:2070 –2074.
30. Gordon NC, Wareham DW. 2010. Multidrug-resistant Acinetobacter
baumannii: mechanisms of virulence and resistance. Int. J. Antimicrob.
Agents 35:219 –226.
31. Leone S, Sturiale L, Pessione E, Mazzoli R, Giunta C, Lanzetta R,
Garozzo D, Molinaro A, Parrilli M. 2007. Detailed characterization of
the lipid A fraction from the nonpathogen Acinetobacter radioresistens
strain S13. J. Lipid Res. 48:1045–1051.
32. Martinic M, Hoare A, Contreras I, Alvarez SA. 2011. Contribution of the
lipopolysaccharide to resistance of Shigella flexneri 2a to extreme acidity.
PLoS One 6:e25557. doi:10.1371/journal.pone.0025557.
33. Lewis LA, Shafer WM, Dutta Ray T, Ram S, Rice PA. 2013. Phosphoe-
thanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipoo-
ligosaccharide modulate binding of complement inhibitors and resistance
to complement killing. Infect. Immun. 81:33– 42.
34. John CM, Liu M, Phillips NJ, Yang Z, Funk CR, Zimmerman LI,
Griffiss JM, Stein DC, Jarvis GA. 2012. Lack of lipid A pyrophosphory-
lation and functional lptA reduces inflammation by Neisseria commen-
sals. Infect. Immun. 80:4014 – 4026.
35. Cullen TW, Madsen JA, Ivanov PL, Brodbelt JS, Trent MS. 2012.
Characterization of unique modification of flagellar rod protein FlgG by
Campylobacter jejuni lipid A phosphoethanolamine transferase, linking
bacterial locomotion and antimicrobial peptide resistance. J. Biol. Chem.
287:3326 –3336.
36. Cullen TW, O’Brien JP, Hendrixson DR, Giles DK, Hobb RI, Thomp-
son SA, Brodbelt JS, Trent MS. 2013. EptC of Campylobacter jejuni
mediates phenotypes involved in host interactions and virulence. Infect.
Immun. 81:430 – 440.
37. Herrera CM, Hankins JV, Trent MS. 2010. Activation of PmrA inhibits
LpxT-dependent phosphorylation of lipid A promoting resistance to an-
timicrobial peptides. Mol. Microbiol. 76:1444 –1460.
38. Falagas ME, Rafailidis PI, Matthaiou DK. 2010. Resistance to polymyx-
ins: mechanisms, frequency and treatment options. Drug Resist. Updat.
13:132–138.
39. Kim SH, Jia W, Parreira VR, Bishop RE, Gyles CL. 2006. Phosphoetha-
nolamine substitution in the lipid A of Escherichia coli O157:H7 and its
association with PmrC. Microbiology 152:657– 666.
40. Ittig S, Lindner B, Stenta M, Manfredi P, Zdorovenko E, Knirel YA, dal
Peraro M, Cornelis GR, Zahringer U. 2012. The lipopolysaccharide from
Capnocytophaga canimorsus reveals an unexpected role of the core-
oligosaccharide in MD-2 binding. PLoS Pathog. 8:e1002667. doi:10.1371
/journal.ppat.1002667.
41. Silipo A, Sturiale L, Garozzo D, Erbs G, Jensen TT, Lanzetta R, Dow
JM, Parrilli M, Newman MA, Molinaro A. 2008. The acylation and
phosphorylation pattern of lipid A from Xanthomonas campestris strongly
influence its ability to trigger the innate immune response in Arabidopsis.
Chembiochem 9:896 –904.
42. Llewellyn AC, Zhao J, Song F, Parvathareddy J, Xu Q, Napier BA,
Laroui H, Merlin D, Bina JE, Cotter PA, Miller MA, Raetz CR, Weiss
DS. 2012. NaxD is a deacetylase required for lipid A modification and
Francisella pathogenesis. Mol. Microbiol. 86:611– 627.
43. Beasley AS, Cotter RJ, Vogel SN, Inzana TJ, Qureshi AA, Qureshi N.
2012. A variety of novel lipid A structures obtained from Francisella tula-
rensis live vaccine strain. Innate Immun. 18:268 –278.
44. Balaji V, Jeremiah SS, Baliga PR. 2011. Polymyxins: antimicrobial sus-
ceptibility concerns and therapeutic options. Indian J. Med. Microbiol.
29:230 –242.
45. Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen
PH. 2007. Comparative evaluation of the VITEK 2, disk diffusion, etest,
broth microdilution, and agar dilution susceptibility testing methods for
colistin in clinical isolates, including heteroresistant Enterobacter cloacae
and Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 51:
3726 –3730.
46. Galani I, Kontopidou F, Souli M, Rekatsina PD, Koratzanis E, Deliola-
nis J, Giamarellou H. 2008. Colistin susceptibility testing by Etest and
disk diffusion methods. Int. J. Antimicrob. Agents 31:434 – 439.
Pelletier et al.
4840 aac.asm.org Antimicrobial Agents and Chemotherapy
 
